Estudio fase 3 de Seguridad y Eficacia de Boceprevir en pacientes con Hepatitis C Crónica genotipo 1 que recayeron tras el tratamiento previo con Peginterferón/Ribavirina". "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin El objetivo principal de este estudio consiste en comparar la eficacia de dos pautas de tratamiento con boceprevir (800 mg tres veces al día [t.v.d.] por vía oral [v.o.]) (en adelante denominado bocep...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The effects of SCH 351125 on mononuclear cell trafficking to joints, synovial inflammation and expression of chemokines in subjects with rheumatoid arthritis Not provided at time of registration

• Pays Netherlands
• Organes Aucun
• Spécialités Aucune

Schering-Plough P04720 : Essai de phase 2 randomisé, en double aveugle évaluant l’efficacité d’un anticorps anti-EGF-1R (SCH 717454) chez des patients ayant un ostéosarcome ou un sarcome d’Ewing. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité d’un anticorps anti-EGF-1R (SCH 717454) chez des patients ayant un ostéosarcome ou un sarcome d’Ewing. Les patients ayant un ostéosarcome opérable s...

• Pays France
• Organes Sarcomes, Os
• Spécialités Thérapies Ciblées

A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus – The ENDURE Study To compare throughout the study the efficacy of PEG-Intron® monotherapy versus standard supportive care, using the time to the first occurrence of any one of the following clinical events (death, live...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients To examine the effect of peg-Intron dose by comparing the "standard" regimen, peg-Intron 1.5 mcg/kg qW sc plus ribavirin 800-1200 mg daily, to a lower dose regimen, peg-Intron 1.0 mcg/kg qW sc plus ri...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Retreatment of hepatitis C non-responsive to Interferon: a placebo controlled randomised trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux Not provided at time of registration

• Pays Belgium, Netherlands
• Organes Aucun
• Spécialités Aucune

Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Have Been Exposed to Pollen in the Vienna Challenge Chamber (VCC) The primary objective of this study is to evaluate the effect on nasal congestion of a maximally tolerated dose of SCH 497079, when taken in combination with DL 5 mg (identified in Phase 1 studies), i...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys The objective of this study is to determine the proportion of chronic hepatitis C genotype 1 subjects who did not respond to previous treatment with Pegasys 180µg QW plus ribavirin, that will achieve ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®) Evaluar la mejoría clínica de la afectación de cadera (en cuanto al dolor, capacidad funcional y rigidez, evaluados por escala WOMAC) en pacientes con EA.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune